搜尋
SpringWorks Therapeutics Inc
SWTX添加自選
46.990USD
0.0000.00%
交易中 （美東）報價延遲15分鐘
3.52B總市值
虧損本益比TTM
關於 SpringWorks Therapeutics Inc 公司
SpringWorks Therapeutics, Inc. 是一家專注於嚴重罕見疾病和癌症的商業階段生物製藥公司。OGSIVEO（nirogacestat）是該公司經美國食品藥品監督管理局 (FDA) 批准的療法。OGSIVEO（nirogacestat）在美國獲批用於治療需要全身治療的進展性纖維瘤成年患者。該公司還擁有多元化的靶向治療產品線，涵蓋實體瘤和血液癌症，項目範圍從臨牀前開發到高級臨牀試驗。其正在進行的開發包括用於治療卵巢顆粒細胞瘤的 Nirogacestat、Nirogacestat 與 B 細胞成熟抗原 (BCMA) 靶向藥物的聯合使用、針對 NF1-PN 的 Mirdametinib 第 2b 期 ReNeu 試驗和 Brimarafenib (BGB-3245)。該公司的早期產品線包括 SW-682，一種在研口服小分子 TEA 結構域 (TEAD) 抑制劑，針對 Hippo 突變型實體瘤進行了評估。
SpringWorks Therapeutics Inc簡介
公司代碼SWTX
公司名稱SpringWorks Therapeutics Inc
上市日期Sep 13, 2019
CEOMr. Saqib Islam, J.D.
員工數量368
證券類型Ordinary Share
年結日Sep 13
公司地址100 Washington Blvd
城市STAMFORD
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編06902-9302
電話12038839490
網址https://www.springworkstx.com/
公司代碼SWTX
上市日期Sep 13, 2019
CEOMr. Saqib Islam, J.D.
SpringWorks Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Chief Operating Officer
Chief Operating Officer
102.78K
--
Mr. Daniel S. (Dan) Lynch
Mr. Daniel S. (Dan) Lynch
Independent Chairman of the Board
Independent Chairman of the Board
82.94K
--
Dr. James (Jim) Cassidy, M.D., Ph.D.
Dr. James (Jim) Cassidy, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
35.86K
+0.02%
Mr. Bhavesh Ashar
Mr. Bhavesh Ashar
Chief Commercial Officer
Chief Commercial Officer
19.30K
--
Mr. Carlos Alban
Mr. Carlos Alban
Independent Director
Independent Director
15.38K
--
Mr. Francis (Frank) Perier, Jr.
Mr. Francis (Frank) Perier, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Herschel S. Weinstein, J.D.
Mr. Herschel S. Weinstein, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Independent Director
Independent Director
--
--
Mr. Daniel Pichl
Mr. Daniel Pichl
Chief People Officer
Chief People Officer
--
-100.00%
Dr. Julie Hambleton, M.D.
Dr. Julie Hambleton, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Chief Operating Officer
Chief Operating Officer
102.78K
--
Mr. Daniel S. (Dan) Lynch
Mr. Daniel S. (Dan) Lynch
Independent Chairman of the Board
Independent Chairman of the Board
82.94K
--
Dr. James (Jim) Cassidy, M.D., Ph.D.
Dr. James (Jim) Cassidy, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
35.86K
+0.02%
Mr. Bhavesh Ashar
Mr. Bhavesh Ashar
Chief Commercial Officer
Chief Commercial Officer
19.30K
--
Mr. Carlos Alban
Mr. Carlos Alban
Independent Director
Independent Director
15.38K
--
Mr. Francis (Frank) Perier, Jr.
Mr. Francis (Frank) Perier, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
常見問題
SpringWorks Therapeutics Inc的前五大股東是誰？
SpringWorks Therapeutics Inc的前五大股東如下：Dr. Badreddin Edris, Ph.D.
有多少機構持有SpringWorks Therapeutics Inc(SWTX)的股份？
截至2025Q2，共有68家機構持有SpringWorks Therapeutics Inc的股份，合計持有的股份價值約為414.43K，占公司總股份的0.55% 。與2025Q1相比，機構持股有所增加，增幅為-8168805.00。